Back to Healio Subcutaneous trastuzumab was observed to have a safety profile and efficacy similar to standard IV administration, offering a viable treatment alternative, according to study ...

Sixty-three patients were enrolled in the phase 2 IMMUN-HER study (NCT03144947) evaluating SC (n = 32) vs IV (n = 31) trastuzumab administration. In the IV trastuzumab arm, 20 of 31 patients (64.5 ...

13, 2018 /CNW/ - Hoffmann-La Roche Limited (Roche Canada) announced today that Health Canada has approved a subcutaneous formulation of HERCEPTIN for the treatment of early and metastatic stage ...

The subcutaneous regimen also reduced pharmacy burdens. Subcutaneous administration of trastuzumab and pertuzumab significantly shortened the time patients with stage I HER2-positive breast cancer ...

Subcutaneous administration of trastuzumab/pertuzumab could save breast cancer patients and healthcare providers substantial amounts of time compared with intravenous ...

Subcutaneous administration of Herceptin Hylecta resulted in non-inferior levels of trastuzumab in the blood (pharmacokinetics) and non-inferior clinical efficacy (pathological complete response ...

We've already seen applications for approval of a subcutaneous form of atezolizumab ... of drugs like Rituxan [rituximab] and drugs like Herceptin [trastuzumab]. We know that this is a formulation ...

Herceptin SC is given as a subcutaneous injection (under the skin) over 2 to 5 minutes every three weeks. More instructions can be found in Section 4. How do I use Herceptin SC? in the full CMI.

Roche has had time to defend Herceptin against biosimilars, however. A patent-protected subcutaneous formulation of the drug was launched some years ago, and now represents 50% or more of the market.

2 Slamon D et al. Adjuvant Trastuzumab in HER2-Positive Breast Cancer. N Engl J Med 2011; 365:1273-83. 3 Pivot, Semiglazov et al. Subcutaneous injection of trastuzumab – analysis of ...